Adherium (ASX:ADR), a global leader in digital respiratory management and developer of the US FDA-cleared Hailie Smartinhaler platform, has exceeded its key commercial milestones for calendar year 2025, with total device shipments surpassing 4,666 units.
The company also exceeded its remote patient monitoring target, with over 2,034 Hailie devices shipped to RPM patients, highlighting strong uptake across both RPM and non-RPM channels.
These milestones mark the most operationally significant growth objectives for Adherium in 2025 and reinforce management’s confidence in sustaining momentum into the new year.
CEO Dawn Bitz said, "Surpassing both our 2,000 RPM shipment goal and 4,000 total patient milestone—and now exceeding 4,600 devices—is a significant validation of our strategy and execution. This performance, continuing through the holiday period, positions us ahead of our previously communicated shipment trajectory."
The RPM channel remains a critical driver of near-term growth, offering direct patient engagement, recurring revenue visibility, and scalable operational capabilities, supporting Adherium's broader objective of reaching 10,000 active RPM patients by the end of 2026.
The company continues to focus on delivering patient shipment and revenue targets while laying the foundation for further expansion in the year ahead.